Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Marvel Clinical Research, LLC

Neither a doctor nor a teaching hospital

Research payments

$13,686,370

4,221 payments

Through program year 2025, Marvel Clinical Research, LLC is reported as receiving $13,686,370 in research payments, across 4,221 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $160,121 64
2024 Research $1,427,467 379
2023 Research $4,075,159 3,732
2022 Research $2,903,535 40
2021 Research $4,920,996 4
2020 Research $194,092 1
2019 Research $5,000 1

Breakdown

Who paid Research payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $4,983,773 10 payments
  2. Moderna TX, Inc. $4,376,739 3,377 payments
  3. AstraZeneca UK Limited $2,590,626 3 payments
  4. Bavarian Nordic A/S $1,174,988 103 payments
  5. Seqirus USA Inc $436,662 703 payments
  6. Sanofi US Services Inc. $100,072 19 payments
  7. Grifols Shared Services North America, Inc. $18,490 4 payments
  8. Genentech, Inc. $5,000 1 payment
  9. E.R. Squibb & Sons, L.L.C. $21 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies (AZD8895 and AZD1061) for Pre-exposure Prophylaxis of COVID-19 $7,328,141 4 payments
  2. A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older $2,520,324 2,926 payments
  3. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,302,055 337 payments
  4. A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age $648,207 65 payments
  5. Nct05238025 $526,781 38 payments
  6. The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older $316,931 251 payments
  7. A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older $228,067 14 payments
  8. A multi-phase, adaptive, randomized, observer-blind, placebo- and active-control study to evaluate the safety, reactogenicity, and immunogenicity of mRNA-based influenza and SARS-CoV-2 multi-component vaccines in healthy adults $201,651 15 payments
  9. A Phase III Randomized Double-blind Placebo-controlled Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442 a Combination Product of Two Monoclonal Antibodies AZD8895 and AZD1061 for Post-exposure Prophylaxis of COVID-19 $166,509 3 payments
  10. A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, 2-Part, Dose-Ranging Study of an EBV Candidate Vaccine,mRNA-1195, in Healthy Adults 18 to 55 Years of Age $124,641 85 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record